Epidural Morphine
ApprovedSmall molecule
Epidural Morphine is one of 38 small molecule programs targeting Spinal Fusion. It is currently in Approved.
1
Indications
4
Total Trials
1
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
48 competitors in Spinal Fusion
#DrugCompanyPhaseTrials
1Medrol
PfizerApproved
MS Contin
HHikma Pharmaceuticals LLC
Approved
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Decadron
AAspen Global Incorporated
Approved
Marcaine
IInnocoll
Approved
Toradol
JJavelin Pharmaceuticals
Approved
Vancocin
HHikma Pharmaceuticals LLC
Approved
Dilaudid
RRhodes Pharmaceuticals, L.P.
Approved
Narcan
SScienture
Approved
Forteo
AAlmaject
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Analgesia2 trials
Two Dose Epidural Morphine for Post-cesarean Analgesia
Terminated·—·Phase 4·NCT01844206·5 enrolled
Epidural1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Epidural Morphine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- UUniversity of Colorado, Denver